RYZB

Bristol Myers completes acquisition of RayzeBio

PremiumThe Fly

5M ago

Bristol Myers announces expiration of tender offer for RayzeBio

PremiumThe Fly

5M ago

The biopharmaceuticals stocks to own in 2024, according to BofA

PremiumThe Fly

7M ago

Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited

JNJ

PremiumThe Fly

7M ago

KRTX

PremiumThe FlyRayzeBio downgraded to Neutral from Overweight at JPMorgan

7M ago

PremiumThe Fly

RayzeBio downgraded to Hold from Buy at Truist

7M ago

FUSN

PremiumThe Fly

Gracell downgrade, Fusion upgrade: Wall Street’s top analyst calls

7M ago

AZN

Recent M&A activity bodes well for Fusion Pharmaceuticals, says Oppenheimer

PremiumThe Fly

7M ago

Fusion Pharmaceuticals upgraded at Raymond James amid radiopharma M&A

PremiumThe Fly

7M ago

RayzeBio deal another ‘incremental positive’ for Bristol, says Morgan Stanley

PremiumThe Fly

7M ago

Cantor says Bristol joins ‘radiopharmaceuticals race’ with RayzeBio deal

KRTX

PremiumThe Fly

7M ago

PremiumThe FlyBristol Myers price target lowered to $68 from $72 at BofA

7M ago

PremiumThe Fly

RayzeBio downgraded to Market Perform from Outperform at William Blair

7M ago

PremiumMarket News

M & A News: Bristol-Myers Squibb (NYSE:BMY) to Buy RayzeBio for $4.1B

7M ago

AZN

RayzeBio jumps 99% to $60.96 after Bristol Myers takeover deal

PremiumThe Fly

7M ago

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

PremiumPress Releases

7M ago

Bristol Myers to acquire RayzeBio for $62.50 per share in cash

PremiumThe Fly

7M ago

RayzeBio to resume trading at 7:30 am ET

PremiumThe Fly

7M ago

PremiumThe FlyBristol Myers to acquire RayzeBio for $62.50 per share in cash

7M ago

PremiumThe Fly

Bristol Myers to acquire RayzeBio for $62.50 per share in cash

7M ago

PremiumPress Releases

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

8M ago